Frequency and characteristics of hematologic and non-hematologic Bortezomib-related toxicity

Published: June 8, 2009
Abstract Views: 181
PDF: 1654
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

ortezomib (Velcade®) is the first of a new class of drugs known as proteasome-inhibitors. Its efficacy has been established in phase II trials SUMMIT and CREST and phase III trial APEX has demonstrated the superiority of Bortezomib (Velcade®) over high-dose dexamethasone in relapsed/refractory multiple myeloma (MM) patients. Although generally well tolerated, several side-effects are correlated to the administration of Bortezomib (Velcade®).

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Varettoni, M. (2009). Frequency and characteristics of hematologic and non-hematologic Bortezomib-related toxicity. Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.383